Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Sensei announces clinical supply agreement with Regeneron for Libtayo » 07:37
01/05/23
01/05
07:37
01/05/23
07:37
SNSE

Sensei Biotherapeutics

$1.54 /

+0.09 (+6.21%)

, REGN

Regeneron

$726.59 /

+6.12 (+0.85%)

Sensei Biotherapeutics…

Sensei Biotherapeutics (SNSE) announced a clinical supply agreement with Regeneron (REGN) for its anti-PD1 therapy Libtayo. The supply agreement supports the evaluation of SNS-101, a conditionally active VISTA-blocking antibody, in combination with Libtayo in a Phase 1/2 trial in solid tumors. Sensei is on track to submit an Investigational New Drug application for SNS-101 in or before April 2023 and the trial is expected to commence in 2023 pending regulatory clearance. "We are excited for the opportunity to work with Regeneron on our planned clinical trial of SNS-101, which has demonstrated strong anti-tumor activity in combination with PD-1 inhibition in preclinical studies. We look forward to exploring the potential of SNS-101 to inhibit tumor growth across a range of indications," said John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics. "We have built a robust preclinical data package supporting the biological rationale for our pH-sensitive approach, which we believe offers both safety and efficacy advantages over pH-independent VISTA antibodies, including the potential to avoid poor pharmacokinetics from target-mediated drug disposition and lower the risk of cytokine release syndrome." Under the terms of the agreement, Sensei will sponsor and fund the planned clinical trial and Regeneron will provide Libtayo. Sensei will maintain global development and commercial rights to SNS-101. Regeneron develops and commercializes Libtayo globally.

ShowHide Related Items >><<
SNSE Sensei Biotherapeutics
$1.54 /

+0.09 (+6.21%)

REGN Regeneron
$726.59 /

+6.12 (+0.85%)

SNSE Sensei Biotherapeutics
$1.54 /

+0.09 (+6.21%)

12/13/22 Citi
Sensei Biotherapeutics initiated with a Buy at Citi
10/03/22 Oppenheimer
Oppenheimer upgrades Sensei Biotherapeutics to Outperform with $5 price target
10/03/22 Oppenheimer
Sensei Biotherapeutics upgraded to Outperform from Perform at Oppenheimer
07/18/22 Oppenheimer
Sensei Biotherapeutics assumed with a Perform at Oppenheimer
REGN Regeneron
$726.59 /

+6.12 (+0.85%)

12/30/22 Oppenheimer
Opco reveals three biotech stocks that will outperform in 2023
11/09/22 RBC Capital
Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital
11/09/22 Truist
Regeneron price target raised to $856 from $790 at Truist
11/03/22 Piper Sandler
Regeneron price target lowered to $765 from $775 at Piper Sandler
SNSE Sensei Biotherapeutics
$1.54 /

+0.09 (+6.21%)

REGN Regeneron
$726.59 /

+6.12 (+0.85%)

REGN Regeneron
$726.59 /

+6.12 (+0.85%)

SNSE Sensei Biotherapeutics
$1.54 /

+0.09 (+6.21%)

REGN Regeneron
$726.59 /

+6.12 (+0.85%)

REGN Regeneron
$726.59 /

+6.12 (+0.85%)

Over a month ago
Initiation
Sensei Biotherapeutics initiated with a Buy at Citi » 09:20
12/13/22
12/13
09:20
12/13/22
09:20
SNSE

Sensei Biotherapeutics

$1.72 /

+0.12 (+7.50%)

Citi analyst Samantha…

Citi analyst Samantha Semenkow initiated coverage of Sensei Biotherapeutics with a Buy rating and $6 price target. Sensei is an early-staged biotech developing next-generation, conditionally active immune checkpoint inhibitors for the treatment of cancer, Semenkow tells investors in a research note. The analyst says that while early, targeting VISTA has potential broad applicability across multiple tumor types. Semenkow sees a favorable risk/reward at current share levels.

ShowHide Related Items >><<
SNSE Sensei Biotherapeutics
$1.72 /

+0.12 (+7.50%)

SNSE Sensei Biotherapeutics
$1.72 /

+0.12 (+7.50%)

10/03/22 Oppenheimer
Oppenheimer upgrades Sensei Biotherapeutics to Outperform with $5 price target
10/03/22 Oppenheimer
Sensei Biotherapeutics upgraded to Outperform from Perform at Oppenheimer
07/18/22 Oppenheimer
Sensei Biotherapeutics assumed with a Perform at Oppenheimer
03/10/22 Piper Sandler
Sensei Biotherapeutics price target lowered to $10 from $12 at Piper Sandler
SNSE Sensei Biotherapeutics
$1.72 /

+0.12 (+7.50%)

SNSE Sensei Biotherapeutics
$1.72 /

+0.12 (+7.50%)

Hot Stocks
Sensei Biotherapeutics sees cash runway into 2H25  07:37
12/08/22
12/08
07:37
12/08/22
07:37
SNSE

Sensei Biotherapeutics

$1.49 /

+0.03 (+2.05%)

 
ShowHide Related Items >><<
SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

10/03/22 Oppenheimer
Oppenheimer upgrades Sensei Biotherapeutics to Outperform with $5 price target
10/03/22 Oppenheimer
Sensei Biotherapeutics upgraded to Outperform from Perform at Oppenheimer
07/18/22 Oppenheimer
Sensei Biotherapeutics assumed with a Perform at Oppenheimer
03/10/22 Piper Sandler
Sensei Biotherapeutics price target lowered to $10 from $12 at Piper Sandler
SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

Hot Stocks
Sensei plans to submit IND application for SNS-101 in or prior to April » 07:37
12/08/22
12/08
07:37
12/08/22
07:37
SNSE

Sensei Biotherapeutics

$1.49 /

+0.03 (+2.05%)

Sensei continues to…

Sensei continues to advance SNS-101 through investigational new drug-enabling studies, and intends to submit an Investigational New Drug application in or prior to April 2023. The Company has reported differentiated preclinical data demonstrating anti-tumor effects, promising pharmacokinetic properties and a superior cytokine release profile compared with non-conditional anti-VISTA therapies. While it advances SNS-101 into the clinic in the near-term, Sensei will continue discovery work for its discovery-stage programs targeting VSIG-4 and ENTPDase1, also known as CD39.

ShowHide Related Items >><<
SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

10/03/22 Oppenheimer
Oppenheimer upgrades Sensei Biotherapeutics to Outperform with $5 price target
10/03/22 Oppenheimer
Sensei Biotherapeutics upgraded to Outperform from Perform at Oppenheimer
07/18/22 Oppenheimer
Sensei Biotherapeutics assumed with a Perform at Oppenheimer
03/10/22 Piper Sandler
Sensei Biotherapeutics price target lowered to $10 from $12 at Piper Sandler
SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

Hot Stocks
Sensei Biotherapeutics appoints Edward van der Horst as CSO » 07:36
12/08/22
12/08
07:36
12/08/22
07:36
SNSE

Sensei Biotherapeutics

$1.49 /

+0.03 (+2.05%)

Robert Pierce, M.D.,…

Robert Pierce, M.D., Sensei's Chief R&D Officer, will move to a consulting role as a Science Fellow, effective December 7, 2022, and Edward van der Horst, Ph.D., Sensei's Senior Vice President, Biologics Discovery & Early Development, has been promoted to Chief Scientific Officer, effective December 7, 2022.

ShowHide Related Items >><<
SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

10/03/22 Oppenheimer
Oppenheimer upgrades Sensei Biotherapeutics to Outperform with $5 price target
10/03/22 Oppenheimer
Sensei Biotherapeutics upgraded to Outperform from Perform at Oppenheimer
07/18/22 Oppenheimer
Sensei Biotherapeutics assumed with a Perform at Oppenheimer
03/10/22 Piper Sandler
Sensei Biotherapeutics price target lowered to $10 from $12 at Piper Sandler
SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

Hot Stocks
Sensei Biotherapeutics closes Boston research site, reduces workforce by 40% » 07:35
12/08/22
12/08
07:35
12/08/22
07:35
SNSE

Sensei Biotherapeutics

$1.49 /

+0.03 (+2.05%)

Sensei Biotherapeutics…

Sensei Biotherapeutics announced a streamlining and realignment of resources to support its key indications and programs, including its lead antibody, SNS-101, a conditionally active antibody targeting the immune checkpoint VISTA, as well as its other TMAb platform programs. In connection with this announcement, the Company will close its research site in Boston and reduce its total workforce by approximately 40%. The Company expects that such reduction in operating expenses, including employee-related costs and reduced occupancy costs, will extend Sensei's estimated cash runway into the second half of 2025. The Company will maintain its Rockville, Maryland research facility, where antibody discovery and production in support of SNS-101 and other TMAb programs is conducted, while maintaining a smaller business office in the Boston area. Sensei plans to relocate any ongoing work at its Boston research site to its Rockville, Maryland site. "Our Board of Directors and management team remain focused on ensuring that Sensei is well positioned to execute on our near-term clinical and preclinical milestones. As we continue to progress the development of SNS-101 towards an IND in the coming months, we have made the strategic decision to reduce our early-stage R&D expenses related to certain discovery stage targets to more closely align with our strategic and financial goals," said John Celebi, President and CEO of Sensei Biotherapeutics. "Today's announcement follows a thoughtful decision-making process, where we ultimately determined that it is in the best interests of the Company to invest our resources where we believe they will have the greatest potential near-term impact. Decisions that impact our people are always extremely difficult, and I would like to express my gratitude to our departing employees for their hard work and service. We are committed to providing support for our impacted colleagues and to helping them identify other opportunities during this transition."

ShowHide Related Items >><<
SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

10/03/22 Oppenheimer
Oppenheimer upgrades Sensei Biotherapeutics to Outperform with $5 price target
10/03/22 Oppenheimer
Sensei Biotherapeutics upgraded to Outperform from Perform at Oppenheimer
07/18/22 Oppenheimer
Sensei Biotherapeutics assumed with a Perform at Oppenheimer
03/10/22 Piper Sandler
Sensei Biotherapeutics price target lowered to $10 from $12 at Piper Sandler
SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

SNSE Sensei Biotherapeutics
$1.49 /

+0.03 (+2.05%)

Conference/Events
Sensei Biotherapeutics management to meet virtually with Oppenheimer » 04:55
12/02/22
12/02
04:55
12/02/22
04:55
SNSE

Sensei Biotherapeutics

$1.43 /

+0.02 (+1.42%)

Virtual Meeting to be…

Virtual Meeting to be held on December 2 hosted by Oppenheimer.

ShowHide Related Items >><<
SNSE Sensei Biotherapeutics
$1.43 /

+0.02 (+1.42%)

SNSE Sensei Biotherapeutics
$1.43 /

+0.02 (+1.42%)

10/03/22 Oppenheimer
Oppenheimer upgrades Sensei Biotherapeutics to Outperform with $5 price target
10/03/22 Oppenheimer
Sensei Biotherapeutics upgraded to Outperform from Perform at Oppenheimer
07/18/22 Oppenheimer
Sensei Biotherapeutics assumed with a Perform at Oppenheimer
03/10/22 Piper Sandler
Sensei Biotherapeutics price target lowered to $10 from $12 at Piper Sandler
SNSE Sensei Biotherapeutics
$1.43 /

+0.02 (+1.42%)

SNSE Sensei Biotherapeutics
$1.43 /

+0.02 (+1.42%)

Conference/Events
Sensei Biotherapeutics management to meet virtually with Oppenheimer » 04:55
11/30/22
11/30
04:55
11/30/22
04:55
SNSE

Sensei Biotherapeutics

$1.39 /

+0.02 (+1.46%)

Virtual Meeting to be…

Virtual Meeting to be held on November 30 hosted by Oppenheimer.

ShowHide Related Items >><<
SNSE Sensei Biotherapeutics
$1.39 /

+0.02 (+1.46%)

SNSE Sensei Biotherapeutics
$1.39 /

+0.02 (+1.46%)

10/03/22 Oppenheimer
Oppenheimer upgrades Sensei Biotherapeutics to Outperform with $5 price target
10/03/22 Oppenheimer
Sensei Biotherapeutics upgraded to Outperform from Perform at Oppenheimer
07/18/22 Oppenheimer
Sensei Biotherapeutics assumed with a Perform at Oppenheimer
03/10/22 Piper Sandler
Sensei Biotherapeutics price target lowered to $10 from $12 at Piper Sandler
SNSE Sensei Biotherapeutics
$1.39 /

+0.02 (+1.46%)

SNSE Sensei Biotherapeutics
$1.39 /

+0.02 (+1.46%)

Conference/Events
Sensei Biotherapeutics management to meet virtually with Oppenheimer » 15:23
11/28/22
11/28
15:23
11/28/22
15:23
SNSE

Sensei Biotherapeutics

$1.37 /

-0.005 (-0.36%)

Virtual Meeting to be…

Virtual Meeting to be held on December 2 hosted by Oppenheimer.

ShowHide Related Items >><<
SNSE Sensei Biotherapeutics
$1.37 /

-0.005 (-0.36%)

SNSE Sensei Biotherapeutics
$1.37 /

-0.005 (-0.36%)

10/03/22 Oppenheimer
Oppenheimer upgrades Sensei Biotherapeutics to Outperform with $5 price target
10/03/22 Oppenheimer
Sensei Biotherapeutics upgraded to Outperform from Perform at Oppenheimer
07/18/22 Oppenheimer
Sensei Biotherapeutics assumed with a Perform at Oppenheimer
03/10/22 Piper Sandler
Sensei Biotherapeutics price target lowered to $10 from $12 at Piper Sandler
SNSE Sensei Biotherapeutics
$1.37 /

-0.005 (-0.36%)

SNSE Sensei Biotherapeutics
$1.37 /

-0.005 (-0.36%)

Conference/Events
Sensei Biotherapeutics management to meet virtually with Oppenheimer » 15:23
11/28/22
11/28
15:23
11/28/22
15:23
SNSE

Sensei Biotherapeutics

$1.37 /

-0.005 (-0.36%)

Virtual Meeting to be…

Virtual Meeting to be held on November 30 hosted by Oppenheimer.

ShowHide Related Items >><<
SNSE Sensei Biotherapeutics
$1.37 /

-0.005 (-0.36%)

SNSE Sensei Biotherapeutics
$1.37 /

-0.005 (-0.36%)

10/03/22 Oppenheimer
Oppenheimer upgrades Sensei Biotherapeutics to Outperform with $5 price target
10/03/22 Oppenheimer
Sensei Biotherapeutics upgraded to Outperform from Perform at Oppenheimer
07/18/22 Oppenheimer
Sensei Biotherapeutics assumed with a Perform at Oppenheimer
03/10/22 Piper Sandler
Sensei Biotherapeutics price target lowered to $10 from $12 at Piper Sandler
SNSE Sensei Biotherapeutics
$1.37 /

-0.005 (-0.36%)

SNSE Sensei Biotherapeutics
$1.37 /

-0.005 (-0.36%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.